BBIO vs SRRK
BBIO: BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in transthyretin amyloidosis and multiple late-stage programs approaching commercialization. SRRK: Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026.
Side-by-side fundamentals
| Metric | BBIO | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $82.66 | $48.30 | |
| Market cap as of 2026-07-23 | $16.2B | $5.9B | |
| PEG as of 2026-07-23 | -3.61 | -0.40 | BBIO lower |
| Net margin as of 2026-07-23 | -124.4% | -237.0% | BBIO higher |
| Gross margin as of 2026-07-23 | +95.1% | n/a | |
| Operating margin as of 2026-07-23 | -90.5% | -231.8% | BBIO higher |
| ROE as of 2026-07-23 | -206.7% | -162.9% | SRRK higher |
| ROA as of 2026-07-23 | -65.8% | -96.3% | BBIO higher |
| Debt / equity as of 2026-07-23 | 8.27 | 0.71 | SRRK lower |
| Revenue growth (YoY) as of 2026-07-23 | +355.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +86.3% | n/a | |
| Beta as of 2026-07-23 | 0.97 | 0.65 | |
| 1-year return as of 2026-07-22 close | +79.6% | +20.8% | BBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.